Teva Could Modify Its "Authorized" Generic Policy Following Ivax Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal worth $7.4 bil. brings Teva a new subsidiary that participates in the authorized generic market.
You may also be interested in...
Global Transformation? Sun Pharma Names Former Teva CEO Israel Makov As Chairman
Experts say the Indian pharma’s strategy may be to drive high growth in RoW markets and enable a transition to professional management.
Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS
Compound fails to meet primary and secondary trial endpoints.
Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS
Compound fails to meet primary and secondary trial endpoints.